Description Discover a new workflow that enables you to effectively combine H&E staining with mIF InSituPlex^® assays and avoid the heat-induced epitope retrieval (HIER) steps that are the root cause of altered H&E staining. We present data showing co-registration of H&E and mIF images with sub-micron accuracy, enabling highly accurate molecular characterization and cellular phenotyping.

Description We present a highly scalable, cost-effective, and reliable AI workflow built with a combination of OMERO Plus, PathViewer, AWS SageMaker, and Ultivue software to efficiently manage mIF big data for digital pathology.

Description Our poster presents a simple, rapid, and robust workflow for performing Ultivue InSituPlex^® mIF assays with OmniVUE^™ panels on the Parhelia Omni-Stainer^™. Tight slide temperature control and lower volume reagent used by the Omni-Stainer^™ supports consistent, high performance, high throughput whole slide multiplexed biomarker detection for translational and clinical studies.

Description We introduce UltiAnalyzer.AI^™, a software tool that integrates a set of artificial intelligence (AI) models designed for fully automatic, highly accurate, highly efficient, and fully scalable whole-slide mIF analysis. By utilizing the wide dynamic range of Ultivue’s InSituPlex^® technology and cloud computing capabilities, this tool increases the robustness, reproducibility, and throughput of mIF analysis in digital pathology.

Description Our ebook describes the implementation and utility of our new pre-optimized flexible multiplexed immunofluorescence assays (FlexVUE panels) to provide the necessary relevant distribution of infiltrating immune cells in tumors. The approach describes how to quickly customize your immune profiling assay to discover the biology most relevant to your research question by starting with the Immuno8 FixVUE panel backbone and switch out up to 2 markers (from a pre-optimized and verified list) to create your own custom 8-plex panel that identifies the immune cell subsets you need to find.

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points. IHC method sare therefore not sufficient for generating the comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. The quantitative assessment of the accuracy and precision of such multiplex panels however is key for their widespread use in clinical samples.

Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points. IHC method sare therefore not sufficient for generating the comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. The quantitative assessment of the accuracy and precision of such multiplex panels however is key for their widespread use in clinical samples.

Description Immunotherapy has transformed the treatment of metastatic and recurrent solid tumors. Advances in technology in the past few years have created unprecedented opportunities to better identify biomarkers of disease processes, especially by using multi-omics technologies and datasets to derive valid and useful signatures of disease. Despite these advances, today only a minority of patients respond to immunotherapies. Prediction of response to therapies such as checkpoint inhibitors that rely on activation of endogenous immune responses has been shown to be especially difficult due to complex and heterogeneous immune escape mechanisms in each patient. Increasing evidence suggests that measurement of robust biomarkers through spatial analysis of the tissue will be key to enable rational patient selection for an improved clinical trial process and design precise combination therapies. To date, much of what has been learned about the tumor microenvironment (TME) has come from the use of IHC, but information has been limited by labor-intensive protocols that yield single data points. IHC method sare therefore not sufficient for generating the comprehensive and interactive picture of the TME landscape. Newer technological approaches, such as multiplex immunofluorescence (mIF), provide greater resolution, better use of precious samples, and unparalleled insight into the spatial cellular arrangement within the tumor. The quantitative assessment of the accuracy and precision of such multiplex panels however is key for their widespread use in clinical samples.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat non-small cell lung cancer (NSCLC) patients. However, most NSCLC patients do not respond to PD-(L)1 blockade as single agents, and intratumoral immune infiltrates involved in the response to these therapies remain poorly characterized. There remains a significant need to understand the biology of response and resistance and the role of infiltrating immune cells. Recent studies have suggested an association between increased B cell infiltration, along with the presence of tertiary lymphoid structures (TLSs) and improved response to immunotherapy in tumors from melanoma, soft tissue sarcoma, and renal cell carcinoma patients. Herein, the webinar will discuss whether intratumoral B cells are beneficial specifically in the context of PD-(L)1 blockade or are a general marker of a better prognosis in metastatic NSCLC.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.